

REMARKS/ARGUMENTS


Applicants submit herewith a substitute Sequence Listing and a corresponding computer-readable substitute Sequence Listing. The sequence information recorded in the corresponding computer-readable substitute Sequence Listing is identical to the paper copy of the substitute Sequence Listing. Support for all of the sequences listed in the substitute Sequence Listing is found in the present application as originally filed.

In SEQ ID NO: 8, the amino acid at position 1 (Abu) has been replaced with the amino acid Gly. Applicants note that, as described at page 24, line 1, of the originally filed specification, "In the above, "Abu" refers to " α -aminoacetic acid". Applicants further note that α -aminoacetic acid is another name for glycine (Gly). Accordingly, this substitution is proper. For the reasons previously described, Abu has also been substituted with Gly in SEQ ID NO: 18. Further, SEQ ID NO's: 20, and 22, section <223> has been amended, as suggested in the Official Communication, to read "Reverse Primer." No new matter has been introduced by the submission of the substitute Sequence Listing and the corresponding computer-readable substitute Sequence Listing.

Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Charles J. Andres, Ph.D.
Attorney of Record
Registration No. 57,537

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)